The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Monoclonal Antibody for Multiple Myeloma Market Research Report 2025
Synopsis
The global Monoclonal Antibody for Multiple Myeloma market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Monoclonal Antibody for Multiple Myeloma in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Monoclonal Antibody for Multiple Myeloma include Bristol Myers Squibb, Abbvie, Janssen Biotech, Karyopharm Therapeutics, PDL BioPharma, Roche and Seattle Genetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Multiple Myeloma.
Report Scope
The Monoclonal Antibody for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Monoclonal Antibody for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibody for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Abbvie
Janssen Biotech
Karyopharm Therapeutics
PDL BioPharma
Roche
Seattle Genetics
Segment by Type
Elotuzumab
Daratumumab
Siltuximab
Dacetuzumab
Rituximab
Others
Segment by Application
Hospital
Drug Center
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Monoclonal Antibody for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Monoclonal Antibody for Multiple Myeloma market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Monoclonal Antibody for Multiple Myeloma in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Monoclonal Antibody for Multiple Myeloma include Bristol Myers Squibb, Abbvie, Janssen Biotech, Karyopharm Therapeutics, PDL BioPharma, Roche and Seattle Genetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Multiple Myeloma.
Report Scope
The Monoclonal Antibody for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Monoclonal Antibody for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibody for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol Myers Squibb
Abbvie
Janssen Biotech
Karyopharm Therapeutics
PDL BioPharma
Roche
Seattle Genetics
Segment by Type
Elotuzumab
Daratumumab
Siltuximab
Dacetuzumab
Rituximab
Others
Segment by Application
Hospital
Drug Center
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Monoclonal Antibody for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Elotuzumab
1.2.3 Daratumumab
1.2.4 Siltuximab
1.2.5 Dacetuzumab
1.2.6 Rituximab
1.2.7 Others
1.3 Market by Application
1.3.1 Global Monoclonal Antibody for Multiple Myeloma Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal Antibody for Multiple Myeloma Market Perspective (2019-2030)
2.2 Monoclonal Antibody for Multiple Myeloma Growth Trends by Region
2.2.1 Global Monoclonal Antibody for Multiple Myeloma Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Monoclonal Antibody for Multiple Myeloma Historic Market Size by Region (2019-2024)
2.2.3 Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Region (2025-2030)
2.3 Monoclonal Antibody for Multiple Myeloma Market Dynamics
2.3.1 Monoclonal Antibody for Multiple Myeloma Industry Trends
2.3.2 Monoclonal Antibody for Multiple Myeloma Market Drivers
2.3.3 Monoclonal Antibody for Multiple Myeloma Market Challenges
2.3.4 Monoclonal Antibody for Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal Antibody for Multiple Myeloma Players by Revenue
3.1.1 Global Top Monoclonal Antibody for Multiple Myeloma Players by Revenue (2019-2024)
3.1.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Players (2019-2024)
3.2 Global Monoclonal Antibody for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Monoclonal Antibody for Multiple Myeloma Revenue
3.4 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio
3.4.1 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody for Multiple Myeloma Revenue in 2023
3.5 Monoclonal Antibody for Multiple Myeloma Key Players Head office and Area Served
3.6 Key Players Monoclonal Antibody for Multiple Myeloma Product Solution and Service
3.7 Date of Enter into Monoclonal Antibody for Multiple Myeloma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Monoclonal Antibody for Multiple Myeloma Breakdown Data by Type
4.1 Global Monoclonal Antibody for Multiple Myeloma Historic Market Size by Type (2019-2024)
4.2 Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Type (2025-2030)
5 Monoclonal Antibody for Multiple Myeloma Breakdown Data by Application
5.1 Global Monoclonal Antibody for Multiple Myeloma Historic Market Size by Application (2019-2024)
5.2 Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Monoclonal Antibody for Multiple Myeloma Market Size (2019-2030)
6.2 North America Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024)
6.4 North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Monoclonal Antibody for Multiple Myeloma Market Size (2019-2030)
7.2 Europe Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024)
7.4 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size (2019-2030)
8.2 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2019-2024)
8.4 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Monoclonal Antibody for Multiple Myeloma Market Size (2019-2030)
9.2 Latin America Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024)
9.4 Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size (2019-2030)
10.2 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024)
10.4 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol Myers Squibb
11.1.1 Bristol Myers Squibb Company Detail
11.1.2 Bristol Myers Squibb Business Overview
11.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Introduction
11.1.4 Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.1.5 Bristol Myers Squibb Recent Development
11.2 Abbvie
11.2.1 Abbvie Company Detail
11.2.2 Abbvie Business Overview
11.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Introduction
11.2.4 Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.2.5 Abbvie Recent Development
11.3 Janssen Biotech
11.3.1 Janssen Biotech Company Detail
11.3.2 Janssen Biotech Business Overview
11.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Introduction
11.3.4 Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.3.5 Janssen Biotech Recent Development
11.4 Karyopharm Therapeutics
11.4.1 Karyopharm Therapeutics Company Detail
11.4.2 Karyopharm Therapeutics Business Overview
11.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Introduction
11.4.4 Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.4.5 Karyopharm Therapeutics Recent Development
11.5 PDL BioPharma
11.5.1 PDL BioPharma Company Detail
11.5.2 PDL BioPharma Business Overview
11.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Introduction
11.5.4 PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.5.5 PDL BioPharma Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Monoclonal Antibody for Multiple Myeloma Introduction
11.6.4 Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Seattle Genetics
11.7.1 Seattle Genetics Company Detail
11.7.2 Seattle Genetics Business Overview
11.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Introduction
11.7.4 Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
11.7.5 Seattle Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Elotuzumab
Table 3. Key Players of Daratumumab
Table 4. Key Players of Siltuximab
Table 5. Key Players of Dacetuzumab
Table 6. Key Players of Rituximab
Table 7. Key Players of Others
Table 8. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Monoclonal Antibody for Multiple Myeloma Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Monoclonal Antibody for Multiple Myeloma Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Monoclonal Antibody for Multiple Myeloma Market Share by Region (2019-2024)
Table 12. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Monoclonal Antibody for Multiple Myeloma Market Share by Region (2025-2030)
Table 14. Monoclonal Antibody for Multiple Myeloma Market Trends
Table 15. Monoclonal Antibody for Multiple Myeloma Market Drivers
Table 16. Monoclonal Antibody for Multiple Myeloma Market Challenges
Table 17. Monoclonal Antibody for Multiple Myeloma Market Restraints
Table 18. Global Monoclonal Antibody for Multiple Myeloma Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Monoclonal Antibody for Multiple Myeloma Market Share by Players (2019-2024)
Table 20. Global Top Monoclonal Antibody for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Multiple Myeloma as of 2023)
Table 21. Ranking of Global Top Monoclonal Antibody for Multiple Myeloma Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Monoclonal Antibody for Multiple Myeloma Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Monoclonal Antibody for Multiple Myeloma Product Solution and Service
Table 25. Date of Enter into Monoclonal Antibody for Multiple Myeloma Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Monoclonal Antibody for Multiple Myeloma Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type (2019-2024)
Table 29. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type (2025-2030)
Table 31. Global Monoclonal Antibody for Multiple Myeloma Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2019-2024)
Table 33. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2025-2030)
Table 35. North America Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 50. Bristol Myers Squibb Company Detail
Table 51. Bristol Myers Squibb Business Overview
Table 52. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product
Table 53. Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 54. Bristol Myers Squibb Recent Development
Table 55. Abbvie Company Detail
Table 56. Abbvie Business Overview
Table 57. Abbvie Monoclonal Antibody for Multiple Myeloma Product
Table 58. Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 59. Abbvie Recent Development
Table 60. Janssen Biotech Company Detail
Table 61. Janssen Biotech Business Overview
Table 62. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product
Table 63. Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 64. Janssen Biotech Recent Development
Table 65. Karyopharm Therapeutics Company Detail
Table 66. Karyopharm Therapeutics Business Overview
Table 67. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product
Table 68. Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 69. Karyopharm Therapeutics Recent Development
Table 70. PDL BioPharma Company Detail
Table 71. PDL BioPharma Business Overview
Table 72. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product
Table 73. PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 74. PDL BioPharma Recent Development
Table 75. Roche Company Detail
Table 76. Roche Business Overview
Table 77. Roche Monoclonal Antibody for Multiple Myeloma Product
Table 78. Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 79. Roche Recent Development
Table 80. Seattle Genetics Company Detail
Table 81. Seattle Genetics Business Overview
Table 82. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product
Table 83. Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 84. Seattle Genetics Recent Development
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal Antibody for Multiple Myeloma Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Monoclonal Antibody for Multiple Myeloma Market Share by Type: 2023 VS 2030
Figure 3. Elotuzumab Features
Figure 4. Daratumumab Features
Figure 5. Siltuximab Features
Figure 6. Dacetuzumab Features
Figure 7. Rituximab Features
Figure 8. Others Features
Figure 9. Global Monoclonal Antibody for Multiple Myeloma Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Monoclonal Antibody for Multiple Myeloma Market Share by Application: 2023 VS 2030
Figure 11. Hospital Case Studies
Figure 12. Drug Center Case Studies
Figure 13. Clinic Case Studies
Figure 14. Others Case Studies
Figure 15. Monoclonal Antibody for Multiple Myeloma Report Years Considered
Figure 16. Global Monoclonal Antibody for Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Monoclonal Antibody for Multiple Myeloma Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Monoclonal Antibody for Multiple Myeloma Market Share by Region: 2023 VS 2030
Figure 19. Global Monoclonal Antibody for Multiple Myeloma Market Share by Players in 2023
Figure 20. Global Top Monoclonal Antibody for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Multiple Myeloma as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Monoclonal Antibody for Multiple Myeloma Revenue in 2023
Figure 22. North America Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Monoclonal Antibody for Multiple Myeloma Market Share by Country (2019-2030)
Figure 24. United States Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Monoclonal Antibody for Multiple Myeloma Market Share by Country (2019-2030)
Figure 28. Germany Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Share by Region (2019-2030)
Figure 36. China Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Monoclonal Antibody for Multiple Myeloma Market Share by Country (2019-2030)
Figure 44. Mexico Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Share by Country (2019-2030)
Figure 48. Turkey Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Bristol Myers Squibb Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 51. Abbvie Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 52. Janssen Biotech Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 53. Karyopharm Therapeutics Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 54. PDL BioPharma Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 55. Roche Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 56. Seattle Genetics Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
